{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(10)"],"submitter":["Huizing M"],"funding":["National Institute of Diabetes and Digestive and Kidney Diseases","National Human Genome Research Institute"],"pubmed_abstract":["<h4>Introduction</h4>Sialic acids are important contributors to the polyanionic component of the glomerular filtration barrier, which regulates permeability selectivity. Pathologic glomerular hyposialylation, associated with podocyte effacement, has been implicated in human and mouse glomerulopathies. Oral treatment with <i>N</i>-acetylmannosamine (ManNAc), the uncharged precursor of sialic acid, ameliorates glomerular pathology in different models of glomerular disease.<h4>Methods</h4>Here we explore the sialylation status of kidney biopsies obtained from 27 subjects with various glomerular diseases using lectin histochemistry.<h4>Results</h4>We identified severe glomerular hyposialylation in 26% of the biopsies. These preliminary findings suggest that this condition may occur relatively "],"journal":["Kidney international reports"],"pagination":["1454-1462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6829193"],"repository":["biostudies-literature"],"pubmed_title":["Rationale and Design for a Phase 1 Study of <i>N</i>-Acetylmannosamine for Primary Glomerular Diseases."],"pmcid":["PMC6829193"],"pubmed_authors":["Anikster Y","Dekel B","Gahl WA","Powell A","Fuentes F","Kopp JB","Leoyklang P","Huizing M","Yardeni T","Chatrathi H","Malicdan MCV","Blake J","Carrillo N","Brede E","Volkov A"],"additional_accession":[]},"is_claimable":false,"name":"Rationale and Design for a Phase 1 Study of <i>N</i>-Acetylmannosamine for Primary Glomerular Diseases.","description":"<h4>Introduction</h4>Sialic acids are important contributors to the polyanionic component of the glomerular filtration barrier, which regulates permeability selectivity. Pathologic glomerular hyposialylation, associated with podocyte effacement, has been implicated in human and mouse glomerulopathies. Oral treatment with <i>N</i>-acetylmannosamine (ManNAc), the uncharged precursor of sialic acid, ameliorates glomerular pathology in different models of glomerular disease.<h4>Methods</h4>Here we explore the sialylation status of kidney biopsies obtained from 27 subjects with various glomerular diseases using lectin histochemistry.<h4>Results</h4>We identified severe glomerular hyposialylation in 26% of the biopsies. These preliminary findings suggest that this condition may occur relatively ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2026-05-02T03:21:40.868Z","creation":"2019-11-15T08:05:22Z"},"accession":"S-EPMC6829193","cross_references":{"pubmed":["31701055"],"doi":["10.1016/j.ekir.2019.06.012"]}}